Steve Davidsen

Steve Davidsen, Ph.D., is Vice President, Oncology Discovery in AbbVie’s R&D organization, where he is responsible for the discovery and research efforts of AbbVie’s Oncology programs. He has been a critical leader in building AbbVie’s Oncology pipeline, directing research teams and partnerships that have led to more than 300 current Oncology trials across a broad range of hematologic and solid tumor indications, and multiple FDA approvals. He has more than 70 scientific publications across a diverse range of topics including metalloproteinase inhibitors, kinase inhibitors, and the discovery of histone deacetylase inhibitors. Steve is a member of AbbVie’s R&D Discovery Research Leadership Team and the Oncology Therapeutic Area Strategy Council. He earned his Ph.D. in organic chemistry from the University of Texas, Austin, and held a post-doctoral position at the University of California, Berkeley before joining Abbott/AbbVie.